Philadelphia, PA (PRWEB) February 03, 2016
Olfactory Biosciences Corp. (OLFC) (OTC Markets ) is pleased to announce the introduction of an advanced nasal decongestion medical device, BREATHEBETTER™.
The BREATHEBETTER™ nasal CMOS micro-vibrating device improves breathing, eliminates dry mouth, prevents snoring and helps with exercise, especially with running.
BREATHEBETTER™ helps with allergies, colds, and deviated septums. With BREATHEBETTER™ the airways are open, and muscle tone throughout the body increases or becomes hyper tonic. http://www.trybreathebetter.com/
BREATHEBETTER™ is CE certified and made of soft silicone FDA standard material. It is harmless and odorless without any side effects. It is an effective, safe and easy device to use. CMOS chips micro-vibrate so that airways are open, and nasal tissue obtains therapy physically. It is drug-free and latex free.
BREATHEBETTER™ is comfortable to wear and most users are completely unaware of any vibrations or even that the device is in place. http://www.trybreathebetter.com/
BREATHEBETTER™ can help users breathe so effectively it may help them increase their energy level after a good night's sleep. It is remarkably affordable and simple to use.
"Compared to adhesive strips on your nose for about $ 180 per year for daily use, BREATHEBETTER™ costs $ 11.95 and lasts for two years. An unbelievable value" noted Rick Stevenson, President of OLFC.
The device has been a huge success in 15 countries including Canada, Australia, Germany, Poland, Russia, Belgium, Chile to mention a few. Over 4 million units have been sold. Because BREATHEBETTER™ works. Go to http://www.trybreathebetter.com/
About Olfactory Biosciences Corp.
Olfactory Biosciences Corp. continues to lead the field of advanced natural medicines with unique external delivery systems. The company develops topical medicine products can modify behavior or provide relief to common behavior challenges.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA